See this article by Goodroot CEO Mike Waterbury as it originally appeared in STAT. After a year defined by record inflation and double-digit health care premium increases, I hope that a few years down the road we can eventually look back at 2023 as the year that ignited change in U.S. health care and led …
Reinventing Health Care in 2023: Goodroot Featured in STAT Read More »
COLLINSVILLE, Conn. — A detailed analysis of the dozen biosimilars for Humira set to enter the market in 2023 found that the downward pressure on drug cost will be minimal, at least initially. The clinical team from Goodroot and its affiliate companies — including RemedyOne, AlignRx, and Nuwae — published a whitepaper that includes projections showing Humira biosimilars …
Humira BioSimilars Unlikely to Produce Short-Term Cost Savings: Goodroot White Paper Read More »
Real Leaders® has announced its 300 Top Impact Companies award winners from around the world. For the second consecutive year, Goodroot is included in the top 100, coming in at number 64 this year and ranking third in the healthcare category. “Every healthcare company is mission-driven and makes an impact,” says Goodroot CEO Mike Waterbury. …
Goodroot Named to Real L️eaders 2023 Top Impact Companies List Read More »
Brian Shonat, Goodroot’s area vice president of business development, recently joined Spencer Smith on the Self-Funded with Spencer podcast to talk about CoeoRx, AlignRx, PBMs, specialty drugs and more. Below are some of the highlights of what Brian had to say during the hour-long chat. Listen to the full episode on the Self-Funded with Spencer …
Goodroot, AlignRx, CoeoRx Highlighted on the Self-Funded with Spencer Podcast Read More »
